Randomized, double-blind, placebo-controlled efficacy and safety study of colesevelam HCl administered to pediatric patients with heterozygous familial hypercholesterolemia on a stable dose of statins [HMG CoA reductase inhibitors] or treatment naive to lipid-lowering therapy.

Trial Profile

Randomized, double-blind, placebo-controlled efficacy and safety study of colesevelam HCl administered to pediatric patients with heterozygous familial hypercholesterolemia on a stable dose of statins [HMG CoA reductase inhibitors] or treatment naive to lipid-lowering therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Colesevelam (Primary)
  • Indications Hyperlipoproteinaemia type II
  • Focus Registrational; Therapeutic Use
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Feb 2010 Results have been published (Journal of Pediatrics 156: 231-236, No. 2, Feb 2010).
    • 07 Oct 2009 The US FDA has approved colesevelam for the treatment of heterozygous familial hypercholesterolaemia in boys and postmenarchal girls based on the results of this trial, according to a Daiichi Sankyo media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top